

Magnesium sulphate only slightly reduces the shivering threshold in humans[†]

A. Wadhwa^{1,2}, P. Sengupta¹, J. Durrani², O. Akça^{1,2}, R. Lenhardt^{1,2}, D. I. Sessler^{1,2}
and A. G. Doufas^{1,2*}

¹OUTCOMES RESEARCHTM Institute and ²Department of Anesthesiology and Perioperative Medicine,
University of Louisville, Louisville, KY, USA

*Corresponding author. E-mail: agdoufas@louisville.edu

Background. Hypothermia may be an effective treatment for stroke or acute myocardial infarction; however, it provokes vigorous shivering, which causes potentially dangerous haemodynamic responses and prevents further hypothermia. Magnesium is an attractive anti-shivering agent because it is used for treatment of postoperative shivering and provides protection against ischaemic injury in animal models. We tested the hypothesis that magnesium reduces the threshold (triggering core temperature) and gain of shivering without substantial sedation or muscle weakness.

Methods. We studied nine healthy male volunteers (18–40 yr) on two randomly assigned treatment days: (1) control and (2) magnesium (80 mg kg⁻¹ followed by infusion at 2 g h⁻¹). Lactated Ringer's solution (4°C) was infused via a central venous catheter over a period of approximately 2 h to decrease tympanic membrane temperature by ~1.5°C h⁻¹. A significant and persistent increase in oxygen consumption identified the threshold. The gain of shivering was determined by the slope of oxygen consumption vs core temperature regression. Sedation was evaluated using a verbal rating score (VRS) from 0 to 10 and bispectral index (BIS) of the EEG. Peripheral muscle strength was evaluated using dynamometry and spirometry. Data were analysed using repeated measures ANOVA; *P* < 0.05 was statistically significant.

Results. Magnesium reduced the shivering threshold (36.3 [SD 0.4] °C vs 36.6 [0.3] °C, *P* = 0.040). It did not affect the gain of shivering (control, 437 [289] ml min⁻¹ °C⁻¹; magnesium, 573 [370] ml min⁻¹ °C⁻¹; *P* = 0.344). The magnesium bolus did not produce significant sedation or appreciably reduce muscle strength.

Conclusions. Magnesium significantly reduced the shivering threshold. However, in view of the modest absolute reduction, this finding is considered to be clinically unimportant for induction of therapeutic hypothermia.

Br J Anaesth 2005; **94**: 756–62

Keywords: brain, protection; complications, hypothermia; complications, shivering; heart, cardiac protection; ions, magnesium; monitoring, temperature; thermoregulation

Accepted for publication: January 21, 2005

Mild hypothermia provides substantial protection against ischaemic brain¹ and myocardial injury^{2,3} in animal models. In humans, mild hypothermia improves neurological outcome in survivors of cardiac arrest,^{4,5} and its application in that setting is now advised by the International Liaison Committee on Resuscitation (ILCOR).⁶ Similarly, the use of hypothermia in patients with ischaemic heart injury is currently under evaluation.⁷

Effective thermoregulatory defences prevent the induction of mild to moderate hypothermia^{7,8} in unanaesthetized patients.⁹ Drugs known to markedly impair thermoregulation are either anaesthetics¹⁰ or major sedatives,¹¹ and they

produce unacceptable amounts of respiratory depression. Thus the search continues for drugs which sufficiently improve thermoregulatory tolerance without simultaneously producing excessive sedation or respiratory depression. In practice, this constitutes a search for drugs which reduce the shivering threshold (triggering core temperature) to a value approximating the target therapeutic core temperature.^{12,13}

Intravenous magnesium has been shown to suppress postoperative shivering,¹⁴ suggesting that this agent reduces the

[†]Data were presented in abstract form at the Annual Meeting of the American Society of Anesthesiologists, San Francisco, CA, 2003.

shivering threshold. Recently, the addition of intravenous magnesium sulphate to a pharmacological anti-shivering regimen increased the cooling rate in unanaesthetized volunteers.¹³ The drug not only exerts a central effect,¹⁵ but is also a mild muscle relaxant¹⁶ and thus may simultaneously reduce the gain of shivering (incremental shivering intensity with progressing hypothermia). Magnesium also confers substantial neurological and cardiac protection in several animal models.^{17–19}

Thus magnesium is an especially attractive candidate for inducing thermoregulatory tolerance since it may simultaneously protect against tissue ischaemia. Therefore we tested the hypothesis that magnesium sulphate administration reduces the threshold and gain of shivering sufficiently to permit the induction of hypothermia without causing clinically significant sedation or muscle weakness.

Methods

With the approval of the Human Studies Committee at the University of Louisville and written informed consent, we studied nine healthy male volunteers. None was obese; taking medications; or had a history of thyroid disease, dysautonomia or Raynaud's syndrome.

Protocol

Volunteers participated on two study days, and they fasted for at least 8 h before each study day. A minimum of 24 h elapsed between the study days. On both days, the volunteers were minimally clothed and rested supine on a standard operating room table. Ambient temperature was maintained near 21°C. On the first study day, each volunteer was randomly assigned in a double-blind manner to receive either normal saline (control) or magnesium. The volunteers were given the alternative treatment on the subsequent study day. On the magnesium day, volunteers were given an i.v. bolus of magnesium sulphate 80 mg kg⁻¹ administered by a syringe pump over a 30-min period. This was followed

by an infusion of 2 g h⁻¹. On the control day, the volunteers received an equal volume of saline. An investigator who was not otherwise involved in the study prepared syringes containing saline or magnesium; thus the study was fully double-blinded.

A catheter was introduced into the superior vena cava via an antecubital vein. This catheter was used for cold-fluid infusion and blood sampling. A venous catheter was inserted in the other arm for drug administration. A circulating-water blanket (Cincinnati Sub-Zero, Cincinnati, OH) and a forced-air blanket (Augustine Medical Inc., Eden Prairie, MN) were placed under and on top of the volunteers, respectively, to maintain mean skin temperature at 31°C throughout the study. Furthermore, the back, upper body, and lower body were individually maintained at the designated value.

After a 30-min i.v. bolus, drug infusion was initiated in order to maintain stable magnesium plasma levels (Fig. 1). Sedation, thermal comfort, and muscle strength were evaluated in the peribolus period. Ten minutes after the beginning of drug infusion, lactated Ringer's solution, cooled to ~4°C, was infused at rates sufficient to decrease the tympanic membrane temperature by ~1.5°C h⁻¹ (cooling phase). Fluid was infused until further reduction in core temperature no longer increased oxygen consumption (see section on data analysis) or a total of 70 ml kg⁻¹ had been given. This is a standard and effective way of reducing core temperature as demonstrated in previous studies. Blood samples were obtained at the end of the drug bolus (post-bolus), 10 min after the initiation of the drug infusion (pre-cooling) and at the shivering threshold (Fig. 1). The volunteers were asked again about their thermal comfort level when the shivering threshold was detected.

Measurements

Heart rate (HR) was measured continuously using an ECG; arterial pressure (MAP) was determined oscillometrically at 5-min intervals at the left ankle. A pulse oximeter continuously determined arterial oxygen saturation (Sa_O₂). End-tidal




Fig 1 Flow diagram of the trial. The various protocol interventions are indicated by arrows (evaluation of muscle strength, drawing of blood samples) and bars (evaluation of thermal comfort and sedation, cooling phase), in relation to the drug administration. The occurrence of the shivering threshold is also indicated by an arrow; the data collected beyond that point were used for the gain of shivering calculation.

carbon dioxide (E'_{CO_2}) and respiratory rate (RR) were measured using a nasal catheter connected to a capnometer device (Datex AS3 monitor, Datex-Engstrom, Ohmeda, Helsinki, Finland). Ambient temperature ($^{\circ}\text{C}$) and relative humidity (%) were also recorded throughout the experiment on each study day.

All body temperatures were measured using Mon-a-therm thermocouples (Tyco-Mallinckrodt Anesthesiology Products Inc., St Louis, MO). Core temperature was recorded from the tympanic membrane. Volunteers inserted the aural probe until they felt the thermocouple touch the tympanic membrane; appropriate placement was confirmed when volunteers easily detected gentle rubbing of the attached wire. The aural canal was occluded with cotton, the probe was securely taped in place and a gauze bandage was positioned over the external ear. Mean skin surface temperature was determined from 15 area-weighted sites.²⁰ Temperatures were recorded from thermocouples connected to calibrated Iso-Thermex 16-channel electronic thermometers which had an accuracy of 0.1°C and a precision of 0.01°C (Columbus Instruments International Corporation, Columbus, OH). Individual and mean skin temperatures were computed by a data acquisition system, displayed at 1-s intervals and recorded at 1-min intervals.

Arteriovenous shunt vasomotor tone was evaluated from forearm–fingertip and calf–toe skin temperature gradients. There is an excellent correlation between skin temperature gradients and volume plethysmography.²¹ Vasoconstriction was defined by a forearm skin temperature gradient $>0^{\circ}\text{C}$.

As in previous studies,^{12,22–27} we used oxygen consumption, as measured by a DeltaTracTM (SensorMedics Corporation, Yorba Linda, CA) metabolic monitor, to quantify shivering; the system was used in canopy mode. Measurements were averaged over 1-min intervals and recorded every minute. Oxygen consumption (VO_2) measurement started immediately after the end of the bolus infusion and lasted throughout the trial. A substantial and sustained increase in VO_2 , $\geq 25\%$ above the baseline, identified the shivering threshold. Exhaust gases from the E'_{CO_2} monitor were returned to the oxygen consumption monitor.

To ascertain that the stability of the magnesium concentrations was within an acceptable clinical level throughout the trial, we obtained blood samples 10 min after the bolus (magnesium or saline) administration, just before the start of active cooling and at the shivering threshold.

Sedation was evaluated using a verbal rating score (VRS) for sleepiness (0=wide awake to 10=asleep) and the bispectral index (BIS) of the electroencephalogram. BIS data were collected using four sensors arranged in a frontotemporal montage after mild abrasion of the skin. Impedance of the sensors was evaluated at 15-min intervals and kept $<5\text{ k}\Omega$. BIS values were transmitted to a data acquisition system every 5 s, and the smoothing window was set at 30 s. Volunteers were advised to keep their eyes closed, especially during the recording period.

Thermal comfort was also evaluated using a VRS (0=worst imaginable cold, 5=adequate thermal comfort, 10=worst imaginable heat). On each study day, sedation level was evaluated before (by VRS), during (VRS and BIS) and after (VRS) bolus administration of magnesium or saline. Thermal comfort (VRS) was evaluated at 3-min intervals during bolus administration and at the shivering threshold.

During bolus administration, cardiorespiratory physiology values (HR, MAP, E'_{CO_2} , RR, SaO_2), mean skin temperatures and core temperature were also evaluated every 3 min. At the same times, laser Doppler flowmetry²⁸ was used to detect changes in the skin blood flow associated with vasodilation. A laser detector was placed on the chest and an increase in values from the baseline of laser Doppler flowmetry indicated increasing blood flow.

Muscle strength was evaluated in the right upper and left lower extremities using a hand-held dynamometer (MICROFET2, Hoggan Health Industries Inc., Draper, UT). This is a simple hand-held device with a small internal load cell capable of measuring muscular force. It is applied to the subject's limb and the subject generates force in an attempt to move the hand-held dynamometer that is held firmly in place by the test administrator.²⁹ The peak force generated after each test is recorded and digitally displayed in pounds (lb). The average of three measurements taken before and after bolus administration was used for further analysis. At the same time as an additional index of peripheral muscle strength, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV_1) were measured using a hand-held spirometer (MicroPlus, Micro Medical Ltd, Rochester, UK).

Data analysis

Threshold differences $<0.5^{\circ}\text{C}$ are of questionable clinical importance. Previous similar studies in volunteers indicate that the standard deviation of shivering threshold measurements is 0.4°C . Thus nine volunteers were required to provide a 90% power to detect a difference of 0.5°C in the shivering threshold with a cross-over design using a paired *t*-test with an α level of 0.05. Kolmogorov–Smirnov and Shapiro–Wilk tests were used to test shivering threshold data for normality.

A substantial and sustained increase in oxygen consumption identified the shivering threshold. The baseline for this analysis was the steady-state value after the bolus administration but before core cooling had started. Maximum intensity of shivering was identified by oxygen consumption which failed to increase further despite continued reduction in core temperature. The gain of shivering was determined by the slope of oxygen consumption vs core temperature regression. Data from the threshold until the maximum intensity of shivering were used for gain calculation. The paired *t*-test was used to compare values between the two treatments.

On each study day haemodynamic and respiratory responses, as well as ambient temperature and relative humidity, were averaged within each volunteer; these values were then averaged across volunteers. The 30-min bolus administration and cooling periods were treated separately.

Interaction between the time (baseline, post-bolus) and the drug (magnesium, saline) administered was evaluated using two-factor analysis of variance (ANOVA). Results of repeated measures during the bolus administration on the two study days were compared using repeated measures ANOVA. To confirm magnesium concentrations were stable, plasma concentrations at the different time-points were compared between the two treatments (magnesium, saline) using two-factor ANOVA (interaction of time with treatment). Results are expressed as mean (SD); $P < 0.05$ was considered statistically significant.

Results

The study subjects were aged 27 (18–40) yr, weighed 88 (14) kg and were 176 (8) cm tall. The data from all nine volunteers were used for the threshold calculation. Technical difficulties with data acquisition prevented the collection of oxygen consumption values in one volunteer after the shivering threshold. Consequently, the gain analysis was based on results from the remaining eight volunteers.

Two-factor ANOVA showed that magnesium serum concentration on both study days was maintained essentially stable over time, from the post-bolus time-point until the shivering threshold ($P = 0.619$) (Table 1).

Sedation increased slightly, but significantly, over time from baseline to post-bolus; however, the increase was similar on the control and magnesium treatments. FVC also decreased slightly, but significantly, over time; again, the reduction was similar on the control and magnesium treatments (Table 2). During the bolus infusion, magnesium increased thermal comfort score and heart rate (Table 3). These changes were not associated with any objective signs of vasodilation and dissipated by the end of the bolus infusion.

Mean skin temperature was maintained near 31°C on each study day throughout the cooling period. All the volunteers were vasoconstricted before the cold fluid infusion started. Vasoconstriction was determined with the forearm to finger temperature gradient. A negative gradient implied

vasoconstriction. Serum concentrations of magnesium remained constant throughout the cooling period for both the control and magnesium treatments, but were more than doubled on the magnesium day. Cardiovascular and respiratory physiology was similar with each treatment. The elapsed time from the initiation of the bolus infusion until the shivering threshold (bolus–shivering interval) was the same between the two treatments (Table 4).

Kolmogorov–Smirnov ($P = 0.150$) and Shapiro–Wilk ($P = 0.684$) tests showed a normal distribution for the shivering threshold data. Magnesium reduced the shivering threshold by 0.3 (0.4) °C (paired t -test; $P = 0.040$) (Fig. 2). The gain of the shivering response was 437 (289) ml min⁻¹ °C⁻¹ for the control and 573 (370) ml min⁻¹ °C⁻¹ for the magnesium treatment ($P = 0.344$) (Table 4).

Discussion

Magnesium is a naturally occurring calcium antagonist and a non-competitive antagonist of *N*-methyl-D-aspartate (NMDA) receptors.³⁰ The exact protective mechanism

Table 2 Sedation and muscle strength before and after bolus administration. Values before and after the 30-min bolus infusion are presented as mean (SD). Interaction of time (baseline, post-bolus) with treatment (control, magnesium) was evaluated using two-factor ANOVA. Muscle strength was measured using a hand-held dynamometer. Forced respiratory volumes were measured using a hand-held spirometer. VRS, verbal rating score for sleepiness; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 s

	Control		Magnesium		P-value	
	Baseline	Post-bolus	Baseline	Post-bolus	Time	Treatment
Sedation level (VRS)	1 (1)	1 (1)	1 (1)	5 (2)	0.010	0.366
Muscle strength in right arm (lb)	39 (7)	43 (14)	40 (10)	36 (16)	0.963	0.447
Muscle strength in left leg (lb)	41 (11)	42 (9)	46 (8)	44 (12)	0.888	0.386
FVC (litre)	4.0 (1.0)	3.5 (0.7)	3.8 (0.7)	3.5 (0.8)	0.011	0.515
FEV ₁ (litre)	3.5 (0.7)	3.4 (1.1)	3.7 (0.7)	3.3 (0.8)	0.298	0.224

Table 3 Results obtained during the bolus magnesium administration. Results obtained at 3-min intervals were first averaged within each volunteer across the 30-min bolus administration period and then averaged among the volunteers for each drug treatment. Repeated measures ANOVA over time was used to compare the two treatments for the presented outcomes. VRS, verbal rating score

	Control	Magnesium	P-value
Core temperature (°C)	36.8 (0.3)	36.6 (0.2)	0.379
Mean skin temperature (°C)	33.6 (1.3)	33.2 (0.7)	0.618
Arm gradient (°C)	1.4 (2.9)	0.7 (2.9)	0.603
Mean arterial pressure (mm Hg)	98 (6)	99 (10)	0.973
Heart rate (beats min ⁻¹)	69 (9)	76 (10)	0.030
SaO ₂ (%)	99 (1)	98 (3)	0.318
Ventilatory frequency (bpm)	19 (4)	17 (2)	0.130
End-tidal CO ₂ (mm Hg)	40 (5)	42 (3)	0.615
Thermal comfort (VRS)	5 (1)	7 (1)	0.019
Sedation (VRS)	5 (3)	5 (2)	0.528
Bispectral index	90 (9)	93 (9)	0.347
Laser flowmetry	21 (16)	11 (8)	0.136

Table 1 Serum magnesium concentrations during the trial. Data are presented as mean (SD). Interaction of time (post-bolus, precooling, shivering) with treatment (control, magnesium) was evaluated using two-factor ANOVA. This analysis confirms that magnesium levels were stable

	Serum [magnesium] (mmol litre ⁻¹)			P-value	
	Post-bolus	Precooling	Shivering	Time	Treatment
Control	0.86 (0.08)	0.86 (0.04)	0.86 (0.04)	0.619	<0.0001
Magnesium	1.89 (0.25)	2.01 (0.21)	2.21 (0.33)		




Fig 2 The shivering threshold for the control and magnesium treatments. The shivering threshold was reduced by 0.31°C on the magnesium treatment day. ($P=0.04$.)

Table 4 Major outcomes and confounding factors during the cooling period. Values above the line space were first averaged over the cooling period and then averaged among the volunteers; values below the line space are at the shivering threshold. *Time elapsed between the initiation of the drug bolus infusion and the shivering threshold. Data are presented as mean (SD). VRS, verbal rating score

	Control	Magnesium	P-value
Ambient temperature (°C)	23.5 (1.4)	23.0 (1.6)	0.444
Relative humidity (%)	27 (6)	30 (5)	0.462
Arm gradient at cooling (°C)	4.5 (3.1)	4.1 (1.6)	0.295
Bolus-shivering interval* (min)	136 (40)	115 (26)	0.266
Mean arterial pressure (mm Hg)	106 (10)	113 (11)	<0.001
Heart rate (beats min ⁻¹)	70 (11)	71 (9)	0.44
Sa _O ₂ (%)	98 (2)	96 (3)	0.003
Ventilatory frequency (bpm)	17 (5)	17 (4)	0.653
End-tidal CO ₂ (mm Hg)	39 (5)	41 (3)	0.010
Serum [Mg] (mmol litre ⁻¹)	0.83 (0.06)	2.22 (0.35)	<0.0001
Total lactated Ringer's solution (litre)	3.2 (2.4)	2.9 (1.1)	0.715
Cooling rate (°C h ⁻¹)	1.2 (0.3)	1.1 (0.4)	0.501
Thermal comfort (VRS)	2 (2)	1 (1)	0.545
Mean skin temperature (°C)	31.0 (0.3)	31.0 (0.2)	0.983
Core temperature (°C)	36.6 (0.3)	36.3 (0.4)	0.040
Gain of shivering (ml min ⁻¹ °C ⁻¹)	437 (289)	573 (370)	0.344

of magnesium remains uncertain, but it probably acts on multiple levels of the ischaemic cascade such as cerebral blood flow,³¹ excitotoxicity,³² energy conservation^{33,34} and vascular homeostasis.³⁵ The cardioprotective effect of magnesium after experimental myocardial infarction is most likely caused by its ability to enhance adenosine production¹⁹ or its antithrombotic effect¹⁸ or both. Because magnesium is safe, inexpensive and readily available, many clinicians favour its use for various ischaemic insults, despite the lack of any clear benefit of magnesium on the mortality and morbidity outcomes after stroke³⁶ or acute myocardial infarction.^{37–39} Magnesium provides excellent neuro- and cardioprotection in various experimental models of ischaemia and has been shown to be an effective treatment

for postoperative shivering. Thus it was an attractive potential agent for facilitating induction of therapeutic hypothermia. However, magnesium at a dose sufficient to raise plasma concentration more than 2-fold only slightly restrained thermoregulatory defences to hypothermia. Compared with those treated with placebo, the shivering threshold in volunteers given magnesium decreased by only 0.3°C to a core temperature of 36.3°C.

Currently, there is little evidence that hypothermia protects against ischaemia in humans, although the evidence is overwhelming in animals. There is certainly little basis for recommending a specific target temperature for therapeutic hypothermia. Nonetheless, target temperatures from 33 to 34°C are being used clinically by some physicians and in ongoing clinical trials. Because magnesium reduces the shivering threshold only about a tenth of the amount necessary, it seems unlikely that magnesium has the potential to facilitate induction of therapeutic hypothermia, at least as a lone agent.

Magnesium seemed likely to induce thermoregulation tolerance because it is an effective treatment for postoperative shivering.¹⁴ That raises the question of how magnesium can be an effective treatment for postoperative shivering, and yet reduce the shivering threshold by only a few tenths of a degree Celsius. The answer is that many postoperative patients have core temperatures only slightly below the normal shivering threshold. This may be the case even when core temperature is relatively low because residual anaesthetics impair thermoregulatory control. Consequently, treatments that reduce the shivering threshold by a few tenths of a degree Celsius may be sufficient to attenuate postoperative shivering.⁴⁰ However, such treatments will be inadequate for induction of therapeutic hypothermia.

Recently, the addition of magnesium sulphate to a meperidine-based pharmacological anti-shivering regimen increased the cooling rate in unaesthetized volunteers.¹³ This effect was attributed to the observed vasodilation in the majority of the volunteers and associated with increased thermal comfort. In our study, increased thermal comfort during magnesium bolus was not related to peripheral vasodilation in our subjects, as determined by extremity temperature gradients. It seems that, despite the modest effect of magnesium on the shivering threshold, this agent could potentially play a contributory role in the induction of therapeutic hypothermia.

Magnesium sulphate, as used clinically, increases cerebrospinal fluid (CSF) magnesium concentrations by only about 20–25%, with a peak concentration reached after 2–4 h depending on the concentration gradient between plasma and CSF.⁴¹ We used an intravenous infusion of magnesium as proposed by Sibai and colleagues⁴² for seizure prophylaxis in pre-eclamptic women. Relatively high plasma concentrations were achieved immediately after the bolus administration; these were maintained until the shivering threshold was reached about 2 h after magnesium bolus initiation, thus ensuring adequate CSF levels. Because

of this, we were unable to determine whether the observed thermoregulatory action of magnesium was of central¹⁵ or peripheral origin.¹⁶

Despite the known central¹⁵ and peripheral muscle relaxation¹⁶ effects of magnesium, we were unable to demonstrate any significant changes in the sedation level or muscle strength during the bolus administration. It is likely that larger doses of magnesium sulphate would produce both greater thermoregulatory effects and a greater risk of complications. Nonetheless, previous studies indicate that the thermoregulatory response to most intravenous drugs is a linear function of plasma concentration.^{43,44} Thus an even larger, potentially hazardous, dose of magnesium seems unlikely to produce a useful reduction in the shivering threshold.

A limitation of our study is that it was conducted in healthy volunteers. Most results from volunteer studies can be extrapolated to patients; however, patients with underlying disease and those who are critically ill may respond differently. Thus it remains possible that magnesium will prove more effective at inducing thermoregulatory tolerance in patients with stroke or other serious neurological problems.

In summary, magnesium in doses sufficient to increase plasma concentrations more than 2-fold reduced the shivering threshold marginally and did not significantly alter the gain of shivering in healthy volunteers. Thus magnesium exerts a clinically unimportant effect as a sole agent; however, it remains to be studied as a potentially useful adjunct for induction of therapeutic hypothermia in patients with stroke or myocardial ischaemia.

Acknowledgements

We appreciate the assistance of Edwin Liem MD, Keith Hanni MD, Teresa Joiner RN, BSN, Gilbert Haugh MS and Nancy Alsip PhD (all from the University of Louisville). This work was supported by NIH Grants GM 61655 and DE 14879 (Bethesda, MD), the Gheens Foundation (Louisville, KY), the Joseph Drown Foundation (Los Angeles, CA) and the Commonwealth of Kentucky Research Challenge Trust Fund (Louisville, KY). O.A. is the recipient of a Research Training Grant from the Foundation for Anaesthesia Education and Research. Mallinckrodt Anesthesiology Products Inc. (St Louis, MO) donated the thermocouples used in this work. None of the authors has any personal financial interest in products related to this research.

References

- 1 Popovic R, Liniger R, Bickler PE. Anesthetics and mild hypothermia similarly prevent hippocampal neuron death in an *in vitro* model of cerebral ischemia. *Anesthesiology* 2000; **92**: 1343–9
- 2 Dae MW, Gao DW, Sessler DI, Chair K, Stillson CA. Effect of endovascular cooling on myocardial temperature, infarct size, and cardiac output in human-sized pigs. *Am J Physiol Heart Circ Physiol* 2002; **282**: H1584–91
- 3 Hale SL, Dae MW, Kloner RA. Hypothermia during reperfusion limits 'no-reflow' injury in a rabbit model of acute myocardial infarction. *Cardiovasc Res* 2003; **59**: 715–22
- 4 Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. *N Engl J Med* 2002; **346**: 557–63
- 5 Group THACAS. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. *N Engl J Med* 2002; **346**: 549–56
- 6 Nolan JP, Morley PT, Vanden Hoek TL, et al. Therapeutic hypothermia after cardiac arrest: an advisory statement by the Advanced Life Support Task Force of the International Liaison Committee on Resuscitation. *Circulation* 2003; **108**: 118–21
- 7 Dixon SR, Whitbourn RJ, Dae MW, et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. *J Am Coll Cardiol* 2002; **40**: 1928–34
- 8 Krieger DW, De Georgia MA, Abou-Chebl A, et al. Cooling for acute ischemic brain damage (cool aid): an open pilot study of induced hypothermia in acute ischemic stroke. *Stroke* 2001; **32**: 1847–54
- 9 Felberg RA, Krieger DW, Chuang R, et al. Hypothermia after cardiac arrest: feasibility and safety of an external cooling protocol. *Circulation* 2001; **104**: 1799–1804
- 10 Annadata RS, Sessler DI, Tayefeh F, Kurz A, Dechert M. Desflurane slightly increases the sweating threshold, but produces marked, non-linear decreases in the vasoconstriction and shivering thresholds. *Anesthesiology* 1995; **83**: 1205–11
- 11 Kurz A, Go JC, Sessler DI, Kaer K, Larson M, Bjorksten AR. Alfentanil slightly increases the sweating threshold and markedly reduces the vasoconstriction and shivering thresholds. *Anesthesiology* 1995; **83**: 293–9
- 12 Doufas AG, Lin CM, Suleman MI, et al. Dexmedetomidine and meperidine additively reduce the shivering threshold in humans. *Stroke* 2003; **34**: 1218–23
- 13 Zweifler RM, Voorhees ME, Mahmood MA, Parnell M. Magnesium sulfate increases the rate of hypothermia via surface cooling and improves comfort. *Stroke* 2004; **35**: 2331–4
- 14 Kizilirmak S, Karakas SE, Akca O, et al. Magnesium sulfate stops postanesthetic shivering. *Ann NY Acad Sci* 1997; **813**: 799–806
- 15 Cotton DB, Hallak M, Janusz C, Irtenkauf SM, Berman RF. Central anticonvulsant effects of magnesium sulfate on N-methyl-D-aspartate-induced seizures. *Am J Obstet Gynecol* 1993; **168**: 974–8
- 16 Lee C, Zhang X, Kwan WF. Electromyographic and mechanomyographic characteristics of neuromuscular block by magnesium sulphate in the pig. *Br J Anaesth* 1996; **76**: 278–83
- 17 McIntosh TK, Vink R, Yamakami I, Faden AI. Magnesium protects against neurological deficit after brain injury. *Brain Res* 1989; **482**: 252–60
- 18 Rukshin V, Shah PK, Cercsek B, Finkelstein A, Tsang V, Kaul S. Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis. *Circulation* 2002; **105**: 1970–5
- 19 Matsusaka T, Hasebe N, Jin YT, Kawabe J, Kikuchi K. Magnesium reduces myocardial infarct size via enhancement of adenosine mechanism in rabbits. *Cardiovasc Res* 2002; **54**: 568–75
- 20 Sessler DI, McGuire J, Moayeri A, Hynson J. Isoflurane-induced vasodilation minimally increases cutaneous heat loss. *Anesthesiology* 1991; **74**: 226–32
- 21 Rubinstein EH, Sessler DI. Skin-surface temperature gradients correlate with fingertip blood flow in humans. *Anesthesiology* 1990; **73**: 541–5
- 22 Doufas AG, Wadhwa A, Lin CM, Shah YM, Hanni K, Sessler DI. Neither arm nor face warming reduces the shivering threshold in unanesthetized humans. *Stroke* 2003; **34**: 1736–40
- 23 Lin CM, Neeru S, Doufas AG, et al. Dantrolene reduces the threshold and gain for shivering. *Anesth Analg* 2004; **98**: 1318–24

- 24 Merilainen PT. Metabolic monitor. *Int J Clin Monit Comput* 1987; **4**: 167–77
- 25 Fritz HG, Hoff H, Hartmann M, Karzai W, Schwarzkopf KR. The effects of urapidil on thermoregulatory thresholds in volunteers. *Anesth Analg* 2002; **94**: 626–30
- 26 Frank SM, Raja SN, Bulcao C, Goldstein DS. Age-related thermoregulatory differences during core cooling in humans. *Am J Physiol Regul Integr Comp Physiol* 2000; **279**: R349–54
- 27 Alfonsi P, Nourredine KE, Adam F, Chauvin M, Sessler DI. Effect of postoperative skin-surface warming on oxygen consumption and the shivering threshold. *Anaesthesia* 2003; **58**: 1228–34
- 28 Johnson JM, Taylor WF, Shepherd AP, Park MK. Laser-Doppler measurement of skin blood flow: Comparison with plethysmography. *J Appl Physiol* 1984; **56**: 798–803
- 29 Bohannon RW, Andrews AWW. Accuracy of spring and strain gauge hand-held dynamometers. *J Orthop Sports Phys Ther* 1989; **10**: 323–5
- 30 Nowak LBP, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. *Nature* 1984; **307**: 462–5
- 31 Chi OZ, Pollak P, Weiss HR. Effects of magnesium sulfate and nifedipine on regional cerebral blood flow during middle cerebral artery ligation in the rat. *Arch Int Pharmacodyn Ther* 1990; **304**: 196–205
- 32 Smith DA, Connick JH, Stone TW. Effect of changing extracellular levels of magnesium on spontaneous activity and glutamate release in the mouse neocortical slice. *Br J Pharmacol* 1989; **97**: 475–82
- 33 McIntosh TK, Faden AI, Yamakami I, Vink R. Magnesium deficiency exacerbates and pretreatment improves outcome following traumatic brain injury in rats: ^{31}P magnetic resonance spectroscopy and behavioral studies. *J Neurotrauma* 1988; **5**: 17–31
- 34 Favaron M, Bernardi P. Tissue-specific modulation of the mitochondrial calcium uniporter by magnesium ions. *FEBS Lett* 1985; **183**: 260–4
- 35 Torregrosa G, Perales AJ, Salom JB, Miranda FJ, Barbera MD, Alborch E. Different effects of Mg^{2+} on endothelin-1- and 5-hydroxytryptamine-elicited responses in goat cerebrovascular bed. *J Cardiovasc Pharmacol* 1994; **23**: 1004–10
- 36 Muir KW, Lees KR, Ford I, Davis S. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke Trial): randomised controlled trial. *Lancet* 2004; **363**: 439–45
- 37 Investigators TMiCMT. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. *Lancet* 2002; **360**: 1189–96
- 38 Group I-FISOLSC. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. *Lancet* 1995; **345**: 669–85
- 39 Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). *Lancet* 1992; **339**: 1553–8
- 40 Talke P, Tayefeh F, Sessler DI, Jeffrey R, Noursalehi M, Richardson C. Dexmedetomidine does not alter the sweating threshold, but comparably and linearly reduces the vasoconstriction and shivering thresholds. *Anesthesiology* 1997; **87**: 835–41
- 41 Fuchs-Buder T, Tramer MR, Tassonyi E. Cerebrospinal fluid passage of intravenous magnesium sulfate in neurosurgical patients. *J Neurosurg Anesthesiol* 1997; **9**: 324–8
- 42 Sibai BM, Lipshitz J, Anderson GD, Dilts PV Jr. Reassessment of intravenous MgSO_4 therapy in pre-eclampsia–eclampsia. *Obstet Gynecol* 1981; **57**: 199–202
- 43 Matsukawa T, Hanagata K, Ozaki M, Iwashita H, Koshimizu M, Kumazawa T. IM midazolam as premedication produces a concentration dependent decrease in core temperature in male volunteers. *Br J Anaesth* 1997; **78**: 396–9
- 44 Matsukawa T, Kurz A, Sessler DI, Bjorksten AR, Merrifield B, Cheng C. Propofol linearly reduces the vasoconstriction and shivering thresholds. *Anesthesiology* 1995; **82**: 1169–80